8.79
0.18 (2.09%)
| Previous Close | 8.61 |
| Open | 8.95 |
| Volume | 909,424 |
| Avg. Volume (3M) | 523,462 |
| Market Cap | 162,204,512 |
| Price / Earnings (Forward) | 21.51 |
| Price / Sales | 1.66 |
| Price / Book | 1.32 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 16 May 2025 |
| Profit Margin | -21.83% |
| Operating Margin (TTM) | 11.24% |
| Diluted EPS (TTM) | -1.10 |
| Quarterly Revenue Growth (YOY) | 13.90% |
| Total Debt/Equity (MRQ) | 28.37% |
| Current Ratio (MRQ) | 2.89 |
| Operating Cash Flow (TTM) | 4.89 M |
| Levered Free Cash Flow (TTM) | 9.40 M |
| Return on Assets (TTM) | -2.19% |
| Return on Equity (TTM) | -16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Bearish | Mixed |
| Health Information Services (Global) | Bearish | Mixed | |
| Stock | OptimizeRx Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.25 |
|
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 6.41% |
| % Held by Institutions | 65.38% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (JMP Securities, 59.27%) | Buy |
| Median | 13.25 (50.74%) | |
| Low | 12.50 (Stifel, 42.21%) | Buy |
| Average | 13.25 (50.74%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.000 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 13 May 2025 | 14.00 (59.27%) | Buy | 0.000 |
| Stifel | 13 May 2025 | 12.50 (42.21%) | Buy | 0.000 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 May 2025 | Announcement | OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance |
| 01 May 2025 | Announcement | OptimizeRx Releases 2025 Environmental, Social, and Governance (ESG) Report |
| 23 Apr 2025 | Announcement | OptimizeRx Sets First Quarter 2025 Conference Call for May 12, 2025, at 4:30 p.m. ET |
| 18 Apr 2025 | Announcement | OptimizeRx Corporation Announces Plan for Additional Board of Directors Refreshment |
| 12 Mar 2025 | Announcement | OptimizeRx Reports Strong Fourth Quarter and Full Year 2024 Financial Results |
| 11 Mar 2025 | Announcement | OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations |
| 10 Mar 2025 | Announcement | OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer |
| 27 Feb 2025 | Announcement | OptimizeRx Sets Fourth Quarter and Full Year 2024 Financial Results Conference Call for March 12, 2025, at 8:30 a.m. ET |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |